FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285732017> ?p ?o ?g. }

• W4285732017 endingPage "4146" @default.
• W4285732017 startingPage "4146" @default.
• W4285732017 abstract "(1) Background: The CDED + PEN (partial enteral nutrition) is a promising method of nutritional treatment in active Crohn’s disease (CD). An increase in fecal calprotectin (FCP) level—a marker of mucosal inflammation—happens to be the first evidence of Crohn’s disease exacerbation that appears ahead of clinical symptoms and usually co-exists with them. In this study, we present our own experience with using the CDED + PEN in the treatment of children with CD and an increased FCP level. (2) Methods: In total, 48 children (male/female: 27/21) aged 4−17 years (median value = 13.43; IQR = 4.00) were treated with CDED + PEN between June 2019 and July 2021. The main inclusion criteria for the study was active CD defined as an FCP level ≥ 250.00 µg/g. Patients with severe clinical manifestation of CD (PCDAI >40.00), as well as ones who started any new concomitant CD treatment later than at least 4 weeks before the start of dietary intervention, were excluded from the analysis. The PCDAI and fecal calprotectin level were assessed at weeks 0 and 12. The primary endpoint was ITT normalization of FCP level, i.e., a result < 250.00 µg/g at week 12. The Wilcoxon Matched Pairs Test was used for statistical analysis. (3) Results: The normalization of the FCP level was obtained in 17 children (35.42%) and an FCP level decrease of at least 50% occurred in 26 patients (54.17%). The reduction in fecal calprotectin level between week 0 and week 12 was statistically significant with a median value of 1045.00 µg/g; IQR = 1188.00, and 363.00 µg/g; IQR = 665.00, respectively (p < 0.05). Among 29 patients who were not in clinical remission at baseline, 16 (55.17%) achieved clinical remission (PCDAI < 10.00) at week 12 and 20 (68.97%) obtained a clinical response defined as at least a 12.50 point drop in PCDAI or remission. In this group, the reduction in PCDAI between baseline and week 12 was statistically significant (median value = 20.00 points; IQR = 7.50 and 5.00 points; IQR = 5.00, respectively (p < 0.05)). All patients with a normal FCP level at week 12 were in clinical remission and 16 (94.13%) of them had a normal CRP (C-reactive protein) value. In 10 children (20.83%) the full course of 12 weeks with CDED + PEN was not completed or the concomitant therapy had been started before week 12 due to the lack of efficacy/intolerance of nutritional treatment. (4) Conclusions: The 12-week course of treatment with the CDED + PEN has a beneficial effect on the fecal calprotectin level in children with active CD. The dietary intervention led to a significant decrease in the FCP level in the studied group and to the normalization of this parameter in every third patient." @default.
• W4285732017 created "2022-07-18" @default.
• W4285732017 creator A5026679912 @default.
• W4285732017 creator A5035946146 @default.
• W4285732017 creator A5044606610 @default.
• W4285732017 creator A5046693338 @default.
• W4285732017 creator A5053608591 @default.
• W4285732017 creator A5060764304 @default.
• W4285732017 creator A5089593455 @default.
• W4285732017 date "2022-07-17" @default.
• W4285732017 modified "2023-10-01" @default.
• W4285732017 title "Effect of the Crohn’s Disease Exclusion Diet (CDED) on the Fecal Calprotectin Level in Children with Active Crohn’s Disease" @default.
• W4285732017 cites W1877809255 @default.
• W4285732017 cites W1966827469 @default.
• W4285732017 cites W1971183592 @default.
• W4285732017 cites W2076777330 @default.
• W4285732017 cites W2077531651 @default.
• W4285732017 cites W2080969130 @default.
• W4285732017 cites W2127694169 @default.
• W4285732017 cites W2134657806 @default.
• W4285732017 cites W237414908 @default.
• W4285732017 cites W2400773242 @default.
• W4285732017 cites W2532466018 @default.
• W4285732017 cites W2586133422 @default.
• W4285732017 cites W2603041755 @default.
• W4285732017 cites W2606398981 @default.
• W4285732017 cites W2609858387 @default.
• W4285732017 cites W2749270116 @default.
• W4285732017 cites W2749325548 @default.
• W4285732017 cites W2790329004 @default.
• W4285732017 cites W2790843066 @default.
• W4285732017 cites W2790882307 @default.
• W4285732017 cites W2803958193 @default.
• W4285732017 cites W2828817391 @default.
• W4285732017 cites W2887951414 @default.
• W4285732017 cites W2897371271 @default.
• W4285732017 cites W2905266065 @default.
• W4285732017 cites W2905376870 @default.
• W4285732017 cites W2948489634 @default.
• W4285732017 cites W2965504771 @default.
• W4285732017 cites W2981768636 @default.
• W4285732017 cites W2984128211 @default.
• W4285732017 cites W2997532536 @default.
• W4285732017 cites W3092023159 @default.
• W4285732017 cites W3212632306 @default.
• W4285732017 cites W3214521508 @default.
• W4285732017 cites W4211167126 @default.
• W4285732017 cites W4226073808 @default.
• W4285732017 cites W4233817719 @default.
• W4285732017 cites W4281606345 @default.
• W4285732017 cites W565121384 @default.
• W4285732017 doi "https://doi.org/10.3390/jcm11144146" @default.
• W4285732017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35887910" @default.
• W4285732017 hasPublicationYear "2022" @default.
• W4285732017 type Work @default.
• W4285732017 citedByCount "2" @default.
• W4285732017 countsByYear W42857320172023 @default.
• W4285732017 crossrefType "journal-article" @default.
• W4285732017 hasAuthorship W4285732017A5026679912 @default.
• W4285732017 hasAuthorship W4285732017A5035946146 @default.
• W4285732017 hasAuthorship W4285732017A5044606610 @default.
• W4285732017 hasAuthorship W4285732017A5046693338 @default.
• W4285732017 hasAuthorship W4285732017A5053608591 @default.
• W4285732017 hasAuthorship W4285732017A5060764304 @default.
• W4285732017 hasAuthorship W4285732017A5089593455 @default.
• W4285732017 hasBestOaLocation W42857320171 @default.
• W4285732017 hasConcept C126322002 @default.
• W4285732017 hasConcept C151730666 @default.
• W4285732017 hasConcept C2777014857 @default.
• W4285732017 hasConcept C2778260677 @default.
• W4285732017 hasConcept C2778292693 @default.
• W4285732017 hasConcept C2779008522 @default.
• W4285732017 hasConcept C2779134260 @default.
• W4285732017 hasConcept C2779280984 @default.
• W4285732017 hasConcept C2779384505 @default.
• W4285732017 hasConcept C61716771 @default.
• W4285732017 hasConcept C71924100 @default.
• W4285732017 hasConcept C86803240 @default.
• W4285732017 hasConcept C90924648 @default.
• W4285732017 hasConceptScore W4285732017C126322002 @default.
• W4285732017 hasConceptScore W4285732017C151730666 @default.
• W4285732017 hasConceptScore W4285732017C2777014857 @default.
• W4285732017 hasConceptScore W4285732017C2778260677 @default.
• W4285732017 hasConceptScore W4285732017C2778292693 @default.
• W4285732017 hasConceptScore W4285732017C2779008522 @default.
• W4285732017 hasConceptScore W4285732017C2779134260 @default.
• W4285732017 hasConceptScore W4285732017C2779280984 @default.
• W4285732017 hasConceptScore W4285732017C2779384505 @default.
• W4285732017 hasConceptScore W4285732017C61716771 @default.
• W4285732017 hasConceptScore W4285732017C71924100 @default.
• W4285732017 hasConceptScore W4285732017C86803240 @default.
• W4285732017 hasConceptScore W4285732017C90924648 @default.
• W4285732017 hasIssue "14" @default.
• W4285732017 hasLocation W42857320171 @default.
• W4285732017 hasLocation W42857320172 @default.
• W4285732017 hasLocation W42857320173 @default.
• W4285732017 hasOpenAccess W4285732017 @default.
• W4285732017 hasPrimaryLocation W42857320171 @default.

• next